Novo Nordisk's Wegovy miss 'will likely raise questions', says investment bank
Ozempic maker Novo Nordisk's (NYSE:NVO) weightloss drug sales were below expectations in the second quarter but this is not a significant concern, analysts said. Sales of Wegovy, the brand for sema...
Is It Too Late to Buy Novo Nordisk Stock After Its 57% Surge?
Novo Nordisk is the leader in the glucagon-like peptide 1 (GLP-1) agonists market with 70% share. The company has notched some big wins with Wegovy this year, opening up several new billion-dollar ...
Ozempic maker Novo Nordisk falls after cutting profit outlook
Shares in Novo Nordisk (NYSE:NVO), the maker of weightloss and diabetes drugs Wegovy and Ozempic, fell over 5% after it slightly lowered the profit outlook for this year. Operating profit for Euro...
Ozempic maker Novo Nordisk misses profit estimates as it builds out capacity
Novo Nordisk, Europe's largest company by market cap thanks to its wildly popular weight-loss drugs, managed just a small increase in second-quarter profits as it builds out the capacity to make th...
Wegovy maker Novo Nordisk posts earnings miss, cuts operating profit outlook
Novo Nordisk on Wednesday announced its second quarter earnings for 2024.
Obesity drugmaker Novo Nordisk misses Q2 profit forecast
Novo Nordisk on Wednesday posted second-quarter operating profit below expectations, raised its 2024 sales forecast but cut profit outlook, as competition from Eli Lilly in the booming weight-loss ...
Novo Nordisk's sales increased by 24% in Danish kroner and by 25% at constant exchange rates to DKK 133.4 billion in the first six months of 2024
Bagsværd, 7 August 2024 - Financial report for the period 1 January 2024 to 30 June 2024 Operating profit increased by 18% in Danish kroner and by 19% at constant exchange rates (CER) to DKK 57.8 b...
US FDA says two more doses of Novo Nordisk's weight-loss drug now available
Two more doses of Novo Nordisk's weight-loss drug, Wegovy, is now available, the U.S. Food and Drug Administration's updated shortages list showed on Tuesday.
Fake weight loss drugs spark warnings on Ozempic supply squeeze
Pharmacists have warned against buying fake weight loss jabs online as shortages of Ozempic persist in the UK. The National Pharmacy Association (NPA) said patients were risking their health over a...
3 Unstoppable Stocks to Buy in August
Novo Nordisk is big but has plenty of room to grow. Vertex Pharmaceuticals' existing products and pipeline programs give it multiple growth catalysts.
Focus: Patients push back against Novo Nordisk move to scrap an insulin product
Novo Nordisk's decision to stop selling its long-acting insulin Levemir in the United States has left some diabetes patients struggling to switch treatments, patients and doctors in a dozen U.S. st...
This Could Send Ozempic's Sales Potential to a Whole Other Level
Ozempic's potential usefulness continues to grow as more studies are done on the diabetes drug. There are multiple potential brain benefits related to using the drug, which could unlock more growth...
Novo Nordisk's Next-Gen Diabetes Candidate Could Challenge Ozempic -- Is the Stock a Buy?
There are dozens of investigational GLP-1 medicines in development. Novo Nordisk, the leader in the field, arguably has the most promising candidates.
Novo Nordisk's Wegovy weight loss drug wins UK approval for use as a heart treatment
The U.K.'s health regulator on Tuesday approved the use of Novo Nordisk's Wegovy weight loss drug to reduce the risk of overweight and obese adults suffering from serious heart problems or strokes....
Novo Nordisk investor backs $100m Alzheimer's funding round
Novo Holdings, the main shareholder of Novo Nordisk (NYSE:NVO), has led a $100 million Series C funding round for Swiss company Asceneuron, which is developing a next-generation treatment for Alzhe...
Related Companies